Marpai Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Marpai şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-6.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-6.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Apr 07

Revenues Not Telling The Story For Marpai, Inc. (NASDAQ:MRAI) After Shares Rise 30%

Marpai, Inc. ( NASDAQ:MRAI ) shares have continued their recent momentum with a 30% gain in the last month alone. Not...

Analiz Makalesi • Feb 16

Investors Still Aren't Entirely Convinced By Marpai, Inc.'s (NASDAQ:MRAI) Revenues Despite 34% Price Jump

Marpai, Inc. ( NASDAQ:MRAI ) shareholders have had their patience rewarded with a 34% share price jump in the last...

Analiz Makalesi • Dec 19

Market Might Still Lack Some Conviction On Marpai, Inc. (NASDAQ:MRAI) Even After 106% Share Price Boost

Marpai, Inc. ( NASDAQ:MRAI ) shares have continued their recent momentum with a 106% gain in the last month alone. Not...

Analiz Makalesi • Jun 29

Not Many Are Piling Into Marpai, Inc. (NASDAQ:MRAI) Stock Yet As It Plummets 28%

To the annoyance of some shareholders, Marpai, Inc. ( NASDAQ:MRAI ) shares are down a considerable 28% in the last...

Seeking Alpha • Aug 19

Marpai rallies after directors buy shares

Marpai (NASDAQ:MRAI) stock is up 9% in premarket trading on Friday after the director increased their holdings in the tech-driven healthcare services provider, as per the latest SEC filings. Director Yaron Eitan bought 1,75,000 shares at the price of $0.79 each, taking his direct beneficial ownership to 9,65,816 shares. Vincent Kane has also bought 6,500 shares at the price range of $0.78 to $0.83 each. The transaction takes Kane's direct beneficial ownership to 71,169 shares. Quick look through company's ownership structure:

Seeking Alpha • Aug 04

Marpai to acquire Maestro Health for $22.1M

Marpai (NASDAQ:MRAI) said Thursday it will acquire Maestro Health, a third-party administrator based in Chicago, Illinois, for $22.1M. The purchase price will be payable in cash on Apr. 1, 2024. Subject to MRAI meeting its obligations under the deal, this payment may be financed over 4 years by the seller. This comprises minimum annual cash payments of $5M, $6M, $8M and $9M payable on Dec. 31, 2024, 2025, 2026 and 2027, respectively. MRAI agreed that a minimum of 35% of net proceeds of any equity offering will be used to pre-pay its minimum payment obligations. The parties agreed that Maestro's free cash position at closing will be $15.79M and it will have certain minimum working capital amounts at closing. Cash on the combined firm's balance sheet (of over $20M) and synergies from the deal are expected to drive the joint company's plan of integration, which is expected to include a target of reaching positive EBITDA within 18 months. The combined company will serve over 40K employee lives, with expected combined proforma annual revenues of ~$40M in 2022. The acquisition is expected to more than double MRAI's revenues and number of customers. The deal is expected to close in 60 days.

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MRAI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MRAI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Marpai Piyasaya Karşı Temettü Getirisi

MRAI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MRAI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.1%
Sektör Ortalaması (Insurance)	2.5%
Analist tahmini (MRAI) (3 yıla kadar)	n/a

Önemli Temettü: MRAI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MRAI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MRAI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MRAI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/11 09:37
Gün Sonu Hisse Fiyatı	2026/09/11 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Marpai, Inc. 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Allen Klee	Maxim Group
null null	Maxim Group
Ashok Kumar	ThinkEquity LLC

Marpai Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Marpai, Inc. announced that it has received $12.1 million in funding

Marpai, Inc. to Report Q4, 2025 Results on Mar 26, 2026

Marpai, Inc. announced that it has received $0.25 million in funding

Marpai, Inc. announced that it has received $0.41 million in funding

Marpai, Inc. Appoints Mimi Davis as President of MarpaiRx

Marpai, Inc. Announces President Changes, Effective January 30, 2026

Marpai, Inc. announced that it has received $0.35 million in funding

Marpai, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Marpai, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Marpai, Inc. Revises Pharmacy Benefit Benefits with Unpreceded Transport and Savings

Marpai, Inc., Annual General Meeting, Aug 27, 2025

Marpai, Inc. to Report Q1, 2025 Results on May 14, 2025

Marpai, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Marpai, Inc. announced that it expects to receive $0.701949 million in funding

Marpai, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Marpai, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Marpai, Inc.(OTCPK:MRAI) dropped from S&P TMI Index

Marpai, Inc.(OTCPK:MRAI) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Independent Director recently sold US$105k worth of stock

Full year 2023 earnings released: US$4.14 loss per share (vs US$5.23 loss in FY 2022)

Consensus revenue estimates decrease by 12%, EPS upgraded

Marpai, Inc. to Report Q1, 2024 Results on May 09, 2024

Marpai, Inc. Announces Executive Appointments

Marpai, Inc. announced that it has received $11.83 million in funding from JGB Management Inc.

Revenues Not Telling The Story For Marpai, Inc. (NASDAQ:MRAI) After Shares Rise 30%

Full year 2023 earnings: EPS misses analyst expectations

Marpai, Inc., Annual General Meeting, May 06, 2024

Nasdaq Panel Grants Marpai's Request for Extension to Comply with Continued Listing Requirements

CEO & Director recently bought US$1.5m worth of stock

Marpai, Inc. announced that it expects to receive $1.5015 million in funding

Marpai, Inc. Provides Impairment Guidance for the Fourth Quarter of 2023

Investors Still Aren't Entirely Convinced By Marpai, Inc.'s (NASDAQ:MRAI) Revenues Despite 34% Price Jump

Marpai, Inc. announced that it has received $1.7 million in funding from Libertas Funding, LLC

Co-Founder & Chairman of the Board recently bought US$193k worth of stock

Marpai, Inc. announced that it expects to receive $1.216464 million in funding

Marpai, Inc. Appoints John Powers as President

New major risk - Shareholder dilution

Market Might Still Lack Some Conviction On Marpai, Inc. (NASDAQ:MRAI) Even After 106% Share Price Boost

Co-Founder & Chairman of the Board recently bought US$99k worth of stock

Marpai, Inc. announced that it expects to receive $0.2955 million in funding

Marpai, Inc. Announces Board Changes

Marpai Receives Delisting Notice from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement and its Securities to be Delisted from the Nasdaq Capital Market

CEO & Director recently bought US$239k worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

New major risk - Share price stability

Marpai, Inc. has withdrawn its Follow-on Equity Offering.

Marpai Inc. Announces CEO Changes

Marpai Receives Non-Compliance Notice From Nasdaq

Marpai, Inc. Executes A Separation Agreement with Mr. Lutz Finger, President of Product and Development

New major risk - Market cap size

New major risk - Revenue and earnings growth

Marpai, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Marpai, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Consensus EPS estimates upgraded to US$2.40 loss

Marpai, Inc. Provides Revenue Guidance for Second Quarter 2023

Marpai Announces Reverse Stock Split in an Effort to Regain Compliance with Nasdaq's Listing Rules

Not Many Are Piling Into Marpai, Inc. (NASDAQ:MRAI) Stock Yet As It Plummets 28%

Marpai, Inc. Launches Marpai Connect Platform to Predict and Help Modify Risk in Healthcare

Marpai, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2023

Marpai, Inc. Hires Gonen Antebi as Chief Operating Officer

Marpai, Inc. Announces Management Changes

Marpai Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Marpai Introduces Chronic Condition Management to Improve Outcomes for Employer Health Plan Members

High number of new and inexperienced directors

Marpai, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Director recently bought US$100k worth of stock

Marpai Launches MarpaiRx Pharmacy Benefit Management Solution to Decrease Prescription Costs

Co-Founder & Chairman of the Board recently bought US$138k worth of stock

Marpai rallies after directors buy shares

Marpai, Inc. (NasdaqCM:MRAI) signed an agreement to acquire Maestro Health for $22.1 million.

Marpai to acquire Maestro Health for $22.1M

Marpai, Inc. to Report Q2, 2022 Results on Aug 10, 2022